Application of botulinum neurotoxin serotype A in preparing medicine for treating raynaud syndrome

Abstract

The invention relates to novel application of botulinum neurotoxin serotype A, namely novel application in preparing a medicine for treating raynaud syndrome. The botulinum neurotoxin serotype A is easy to use for operation, low in cost, safe and small in pain when used for treating raynaud syndrome, can overcome the defects that the medicine acts to blood vessels of a whole body in a general oral, intramuscular or intravenous administration, the dose is difficult to hold, the side effect is high and the like, and can also overcome the defects of large surgical wound, more complications and high relapse rate of surgical treatment, so that the application is an innovation to various traditional treatment means ideally and methodologically.

Description

technical field [0001] The invention relates to a new application of type A botulinum toxin, that is, a new application in the preparation of medicines for treating Raynaud's syndrome. Background technique [0002] Raynaud's syndrome is a group of syndromes in which the fingers (toes) become pale, purple, and then flushed due to cold or emotional agitation. Those who have no specific cause are called idiopathic Raynaud syndrome; those who are secondary to other diseases are called secondary Raynaud syndrome. [0003] The etiology of idiopathic Raynaud's syndrome is unknown, and it may be related to cold stimulation, nervous excitement, occupational factors, endocrine disorders and other factors. Secondary Raynaud's syndrome is often accompanied by the following diseases: systemic scleroderma, systemic lupus erythematosus, dermatomyositis or polymyositis, rheumatoid arthritis, atherosclerosis of extremities in patients over 50 years old, thrombotic Vasculitis, primary pulmo...

AI Technical Summary

Problems solved by technology

[0006] The defect of current drug therapy is that the general drug method (oral, intramuscular injection or intravenous administration) makes the drug act on the blood vessels of the whole body, while RS only involves the extremity blood vessels, and it is a chronic process, so the drug therapy has certain difficulties: medication If the dose is not large, the symptoms will not be easily eliminated: if the dose is increased, it can cause side effects such as lower blood pressure and faster heart rate, especially not suitable for patients with insufficient blood supply to the original myocardium or brain

In addition, oral administration of large doses of vasodilation drugs can often cause adverse effects such as gastrointestinal reactions and skin reactions; the mechanism of surgical treatment of RS is to relieve symptoms by blocking the sympathetic nerve fibers that control extremity vascular activity, including upper thoracic sympathetic nerve fibers. Nervous blockade, lumbar sympathectomy or block, sympathectomy in the adventitia of medium and small arteries (resection of the adventitia can range from digital artery, digital palmar proper artery, digital palmar artery, superficial palmar arch to Radial ulnar artery) and other surgical methods have disadvantages such as large surgical trauma, many complications, and high recurrence rate, which limit the clinical application